Skip to the page
pepts.wiki

We are not doctors and nothing here is medical advice. Always consult a medical professional first. Why we say this

Licensed medicineStub

PT-141

Melanocortin receptor agonist (bremelanotide)

A cyclic peptide derived from Melanotan II. As bremelanotide it is licensed in the United States for hypoactive sexual desire disorder in premenopausal women.

Reconstitution calculator

At a glance

Licensed medicine

A regulator has licensed it for at least one use, in at least one country. That says nothing about uses outside the license.

This page is a stub

The wiki has this compound's identity from the My-Pepts library, its standing, and what PubMed holds for it. The article, with its studies read and cited, is not written yet. Until it is, the counts below say how much research exists, not what it found.

How strong is the evidence

How far it has climbed

Every medicine climbs the same ladder. Most compounds never reach the top, and where one stands says how much its claims can carry.

  1. Licensed medicine: PT-141

    A regulator has reviewed the trials and licensed it for a named use.

  2. Phase 3

    Large randomized trials, often thousands of people, against placebo or a standard treatment.

  3. Phase 2

    Mid-sized trials that measure dose against effect in people with the condition.

  4. Phase 1 and early human studies

    First studies in people: safety, and how the body handles it.

  5. Cells and animals

    Laboratory and animal work. An animal result is not a result in people.

114
papers on PubMed
84
of them in people
14
randomized trials
58
reviews

A count says how much has been published, not what it found. Counted on PubMed: 2026-11-16

Handling and reconstitution

From powder to a measured sample

The same four steps for any lyophilized vial. Laboratory handling, not use in a person.

  1. 1. Read the vial

    The label gives the mass of peptide in the vial, in milligrams. That number is the start of every calculation.

  2. 2. Add the diluent

    A measured volume of diluent goes in slowly, down the glass. Swirl gently; shaking can damage a peptide.

  3. 3. Work out the strength

    Concentration is mass divided by volume: 10 mg in 2 mL is 5 mg per mL.

  4. 4. Measure the sample

    Volume is the mass wanted divided by the concentration. On a U-100 syringe, 1 mL is 100 units.

The calculator below does the arithmetic and shows its working.

As powder

General practice for lyophilized peptides: keep the sealed vial frozen or refrigerated, dry and away from light, and follow the supplier's certificate of analysis.

In solution

Once in solution a peptide is kept refrigerated and used within the period the supplier states. A vial drawn from more than once needs a preserved diluent such as bacteriostatic water.

This is general practice for lyophilized peptides, not data on PT-141 itself. The batch's certificate of analysis and the supplier's sheet are the facts to go by. More on storage

Reconstitution calculator

Opens on vial sizes common for research peptides. Change any number. How the arithmetic works

Draw to

10 units

0.1 mL on a U-100 syringe

Concentration
2.5 mg/mL
Each unit holds
25 mcg
Samples in the vial
20
Sample
250 mcg

5 mg in 2 mL is 2.5 mg/mL. 250 mcg of that is 0.1 mL, which reads as 10 units. This is arithmetic for a vial of PT-141; no amount here is a recommendation.

PT-141: on PubMed

What PubMed held for PT-141 on November 16, 2026. A count says how much a compound has been studied, not what the studies found: how to read these numbers.

114
papers
84
in humans
16
clinical trials
14
randomized trials
2012: 2 papers122013: 0 papers2014: 2 papers142015: 2 papers2016: 2 papers162017: 5 papers2018: 4 papers182019: 6 papers2020: 7 papers202021: 10 papers2022: 14 papers222023: 8 papers2024: 8 papers242025: 13 papers2026: 12 papers so far26
Papers per year, 2012 to 2026. The most in one year: 14.

Most relevant on PubMed

Listed by PubMed's own relevance ranking, trials and reviews first. The wiki has not read these into the article unless they are also among its sources.

  1. PT-141: a melanocortin agonist for the treatment of sexual dysfunction

    TrialMolinoff PB, Shadiack AM, Earle D, et al. Annals of the New York Academy of Sciences, 2003. PMID 12851303

  2. Female Sexual Desire, Arousal, and Orgasmic Dysfunctions: A Systematic Review and Meta-Analysis of Treatment Options

    Meta-analysisToledo RG, Winkelman WD, Reyes-Gonzalez D, et al. Journal of minimally invasive gynecology, 2026. PMID 40543759

  3. Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women

    Meta-analysisSpielmans GI Journal of sex research, 2021. PMID 33678061

  4. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials

    Randomized trialKingsberg SA, Clayton AH, Portman D, et al. Obstetrics and gynecology, 2019. PMID 31599840

  5. Safety Profile of Bremelanotide Across the Clinical Development Program

    Randomized trialClayton AH, Kingsberg SA, Portman D, et al. Journal of women's health (2002), 2022. PMID 35147466

  6. Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder

    ReviewMayer D, Lynch SE The Annals of pharmacotherapy, 2020. PMID 31893927

  7. An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder

    ReviewCipriani S, Alfaroli C, Maseroli E, et al. Expert opinion on pharmacotherapy, 2023. PMID 36242769

  8. Bremelanotide: First Approval

    ReviewDhillon S, Keam SJ Drugs, 2019. PMID 31429064

Search used: (bremelanotide[tiab] OR "PT-141"[tiab]). Run it on PubMed

Research links

Also in Hormonal